MedCity News November 6, 2024
Acadia Pharmaceuticals did not disclose the buyer of the priority review voucher. The biotech received the voucher last year alongside the regulatory decision that made its drug Daybue the first FDA-approved treatment for the rare disease Rett syndrome.
Acadia Pharmaceuticals committed a lot of money for rights to Daybue, which in the biotech’s hands became the first FDA-approved drug for the rare neurological disorder Rett syndrome. That approval came with a regulatory fast pass for a future drug, and Acadia is now capitalizing on it with a deal to sell the voucher for $150 million.
The San Diego-based biotech did not disclose the buyer of the priority review voucher. But when the deal closes, $50 million of the proceeds from...
Today's Sponsors
Today's Sponsor